The Global CAR T-Cell Therapy Market is Projected to Reach More Than USD 22.2 Billion by 2032 from USD 2.1 Billion in 2023, Growing at a CAGR of 30% from 2024-2032 | Astute Analytica

The global 𝐂𝐀𝐑 𝐓-𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐦𝐚𝐫𝐤𝐞𝐭 is set for remarkable growth, with projections indicating an increase from 𝐔𝐒𝐃 𝟐.𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 to more than 𝐔𝐒𝐃 𝟐𝟐.𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐. This impressive growth trajectory, marked by a compound annual growth rate (𝐂𝐀𝐆𝐑) 𝐨𝐟 𝟑𝟎% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟐, underscores the transformative potential and increasing adoption of CAR T-cell therapies in treating various types of cancer.

𝐓𝐡𝐞 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞- https://www.astuteanalytica.com/request-sample/car-t-cell-therapy-market

CAR T-cell therapy, a form of immunotherapy that harnesses the body's own immune cells to combat cancer, has shown significant promise in clinical trials and real-world applications. The therapy involves modifying a patient's T-cells to express a chimeric antigen receptor (CAR) that targets cancer cells, leading to their destruction.

Key factors driving the growth of the CAR T-cell therapy market include advancements in biotechnology, increasing incidence of cancer worldwide, and a growing focus on personalized medicine. Additionally, favorable regulatory environments and substantial investments in research and development are accelerating the commercialization of CAR T-cell therapies.

Novartis AG
Bluebird Bio, Inc.
Cellectis
Bristol-Myers Squibb
Merck & Co., Inc.
Juno Therapeutics, Inc.
Celyad Oncology
Celgene Corporation
Sorrento Therapeutics, Inc.
Miltenyi Biotech
Intellia Therapeutics
Pfizer, Inc.
Autolus Therapeutics
Gilead Sciences, Inc. (Kite Pharma Inc.)
Cartesian Therapeutics, Inc.
Caribou Biosciences, Inc.
Other Prominent Players

North America currently dominates the CAR T-cell therapy market, owing to its advanced healthcare infrastructure, strong presence of key industry players, and extensive research activities. However, other regions, including Europe and Asia-Pacific, are expected to witness significant growth due to rising healthcare expenditures, increasing awareness about cancer immunotherapies, and supportive government initiatives.

The competitive landscape of the CAR T-cell therapy market is characterized by strategic collaborations, mergers and acquisitions, and continuous innovations by leading companies. Major players in the market include Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Celgene Corporation, among others.

As the CAR T-cell therapy market continues to expand, it holds the promise of revolutionizing cancer treatment and improving patient outcomes. The anticipated growth to USD 22.2 billion by 2032 reflects the growing confidence in this cutting-edge therapy to deliver life-saving solutions for cancer patients globally.

𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧, 𝐩𝐥𝐞𝐚𝐬𝐞 𝐯𝐢𝐬𝐢𝐭:- https://www.astuteanalytica.com/industry-report/car-t-cell-therapy-market

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

By Indication

Leukemia
Lymphoma
Myeloma
By Source

Autologous
Allogenic
By Type of Therapy

Monotherapy
Combination therapy
By Product

ABECMA
Breyanzi
Carvykti
Kymriah
Tecartus
Yescarta
By Administration Setting

Inpatient
Outpatient
By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Rest of South America

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭@- https://www.astuteanalytica.com/request-sample/car-t-cell-therapy-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐬𝐭𝐮𝐭𝐞 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.
They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyse for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Get in touch with us
Phone number: +18884296757
Email: sales@astuteanalytica.com
Visit our website: https://www.astuteanalytica.com/
LinkedIn | Twitter | YouTube | Facebook

This release was published on openPR.